FDX1 and non-small cell lung carcinoma: To enhance diagnostic efficacy, a multi-autoantibody signature (anti-DLAT/LIAS/FDX1/COPT1) was constructed, which significantly improved discrimination (NSCLC <i>vs</i> NC: AUC = 0.805; NSCLC <i>vs</i> BPN: AUC = 0.751).